Two drugs have reshaped how we think about obesity, diabetes, and cardiovascular disease: Semaglutide (Wegovy/Ozempic by Novo Nordisk; Poviztra by Emcure in India) and Tirzepatide (Mounjaro by Eli Lilly; YurPeak by Cipla in India). Both are injectable GLP-1 receptor agonists, but Tirzepatide also activates the GIP receptor, giving it a dual mechanism, the positive effects of which clearly shows up in the trial data.
I put together this comparison after spending a few weeks reading through the major trials. The post compares the effect of the two drugs on weight loss, cardiovascular events, heart failure, inflammation, and cancer signals — with trial names so you can look things up yourself.
TL;DR
- For weight loss alone, Tirzepatide wins: 15–22% body weight reduction vs 12–16% for Semaglutide over about a year. Both are impressive, but the head-to-head trial (SURMOUNT-5) confirmed Tirzepatide's edge.
- For cardiovascular protection, Semaglutide has stronger evidence right now. SELECT showed a 20% reduction in heart attacks, strokes, and cardiovascular death — even in people without diabetes. Tirzepatide's equivalent trial (SURMOUNT-MMO) is still ongoing.
- For heart failure, both help. SUMMIT showed Tirzepatide reduced heart failure hospitalisations by 32–38% in obese patients with a common form of heart failure (HFpEF) that previously had very few treatment options.
- For inflammation, both lower C-reactive protein (a blood marker of systemic inflammation), but Tirzepatide's ~37% reduction in SUMMIT is among the strongest seen in any metabolic drug trial. This effect kicks in early, sometimes before significant weight loss.
- For cancer risk, neither drug increases risk. Both show early signals toward lower rates of obesity-related cancers (endometrial, breast, colorectal), though the data is observational and not yet conclusive.
Primary takeaways
- Weight loss: Tirzepatide has a clear efficacy edge. The practical decision in India probably comes down to availability and cost — Emcure's Poviztra (Semaglutide) or recent generic versions which are even cheaper vs Cipla's YurPeak (Tirzepatide).
- Cardiovascular risk: Semaglutide is the only one with hard outcome data showing reduced heart attacks and strokes, and that holds even without diabetes. Tirzepatide may well show the same, but the trial isn't done yet.
- Heart failure (HFpEF): Tirzepatide's SUMMIT results are impressive here — this was a population with very few options before.
- These stack with existing meds. The benefits are additive on top of statins, BP drugs, etc.
- These drugs reduce inflammation alongside weight. The anti-inflammatory signal (hs-CRP) shows up early and seems partly independent of how much weight you lose, which has been linked to improved health outcomes independent of reduction in weight or cholesterol levels.
Detailed Comparison
| Domain / Outcome | Semaglutide (SC 0.5–1 mg; 2.4 mg) | Tirzepatide (5–15 mg) | Key Trials / Sources |
|---|---|---|---|
| Weight Loss (Obesity, non-diabetic) | ~12–16% loss of starting body weight over 12–15 months (2.4 mg). Predictable and dose-dependent. | ~15–22% loss of starting body weight over 12–15 months. Currently the most potent approved drug. | STEP 1, STEP 3, STEP 4, SURMOUNT-1, SURMOUNT-5 |
| Weight Loss (Type 2 Diabetes) | Typically 6–10% depending on dose and baseline diabetes severity. | 12–15% even in T2DM; consistently superior to Semaglutide in combined analyses. | SURPASS-2, STEP 2 |
| Major cardiovascular events (Heart attack, stroke, cardiovascular death) | ~20–26% reduction in MACE vs placebo in SUSTAIN-6 & SELECT. Hazard ratios ~0.74–0.80. | SURPASS-4 shows safety (neutral); SURPASS-CVOT topline shows non-inferiority vs dulaglutide with slight advantage (~8% lower). | SUSTAIN-6, PIONEER-6, SELECT, SURPASS-4, SURPASS-CVOT |
| Cardiovascular Outcomes in Obesity without Diabetes | Strong evidence: SELECT showed a 20% reduction in MACE in people with obesity + known CVD but NO diabetes. | Evidence pending: SURMOUNT-MMO ongoing (no results yet). | SELECT, SURMOUNT-MMO |
| Heart Failure Outcomes (hospitalization, breathlessness, quality of life) | Benefit present: SELECT subgroup analyses show reduced HF hospitalizations and improved symptoms across HF subtypes. | Benefit present: SUMMIT trial showed ≈32–38% reduction in HF events + improved exercise tolerance in HFpEF + obesity. | SUMMIT, SELECT HF analysis |
| Reduction in Chronic Inflammation (hsCRP marker) | hsCRP reduction by ~12–20% early; up to ~30–40% over long term. Anti-inflammatory effect occurs even before major fat loss. | hsCRP reduction by ~37% in SUMMIT; one of the strongest anti-inflammatory drug responses seen in metabolic drug trials. | STEP inflammation analysis, SELECT biomarkers, SUMMIT biomarkers |
| Other Inflammatory Markers (IL-6, TNF-α) | Consistent decreases across metabolic trials; partly independent of weight loss. | Consistent decreases; driven by large visceral fat loss + improved metabolic signaling. | Semaglutide inflammation review, GLP-1 RA inflammatory markers meta-analysis |
| Colorectal Cancer (CRC) Risk | Multiple observational studies show lower CRC incidence vs insulin, metformin, SGLT2i. No increased risk in meta-analyses. | Early real-world data show neutral to lower CRC risk; no signal suggesting increased risk. | JAMA Oncology CRC 2024, Tirzepatide cancer meta-analysis |
| Overall Cancer Risk | Meta-analysis: no increased risk of total cancer, pancreatic cancer, thyroid cancer, etc. Possible protective effect in obesity-related cancers. | Meta-analysis shows no increase; 10 mg dose possibly associated with lower overall cancer rates (exploratory). | GLP-1 RA cancer meta-analysis, thyroid/pancreatic cancer review |
| Obesity-Related Cancers (endometrial, ovarian, breast, GI) | Large cohort data show ~7–10% lower risk vs non–weight-loss diabetes drugs. Strong reduction seen in women. | Registry data show neutral or lower risk; long-term results still unavailable since it is a newer drug. | ASCO 2025, eClinicalMedicine 2025 |
| Kidney Cancer Risks | Slight risk in some retrospective datasets but not confirmed in RCTs. Under observation. | No dose-related risk reported so far. | JAMA Oncology EHR analysis |
| Mechanistic Anti-Cancer Effects | GLP-1 receptor activation reduces insulin/IGF signaling, visceral fat, chronic inflammation → potential cancer risk reduction pathways. | Similar mechanisms; stronger metabolic effects → potential stronger indirect cancer-risk reduction (not proven). | GLP-1/GIP receptor biology, dual agonist mechanisms |
Are GLP-1 drugs worth it?
Unequivocally, yes. GLP-1 drugs have changed the face of modern medicine. The US adult obesity rate dropped from 39.9% to 37.0% between 2022 and 2025 — the first meaningful decline in decades — coinciding with GLP-1 usage for weight loss doubling to 12.4% of American adults. Population-level cardiovascular data will take years to materialise, but the trial evidence speaks for itself: SELECT showed a 20% reduction in heart attacks and strokes in people with obesity who didn't even have diabetes. That is a large effect size for a single drug.
On raw efficacy, Tirzepatide wins versus Semaglutide in most matchups — better weight loss, fewer heart failure events, and lower inflammation. The market reflects this: Eli Lilly's combined tirzepatide revenue crossed $36.5 billion in 2025, overtaking Novo Nordisk's semaglutide portfolio. The dual GIP/GLP-1 mechanism clearly outperforms GLP-1 alone.Tirzepatide's major cardiovascular outcomes trial (SURMOUNT-MMO) hasn't reported yet — it may well close the evidence gap on hard CV endpoints. And neither drug class has 10+ year safety data.The next generation is already in trials. Eli Lilly's retatrutide, a triple GLP-1/GIP/glucagon agonist, showed 24% weight loss in Phase 2 and 28.7% in its first Phase 3 readout. If approved, it would leapfrog both current drugs on efficacy.
But efficacy rankings matter less when the drug is unaffordable. In India, both Mounjaro and branded Ozempic are out of reach for the vast majority. The recent arrival of generic semaglutide changes this equation. India's generic drug industry has done this before — Cipla's $1-a-day HIV antiretroviral cocktail saved millions of lives when the branded version cost $14,000 a year.
This matters because the treatment gap in India is enormous. Among Indians with diabetes, only 27% are aware of their condition and just 7% have it under control — and the poorest are 12% less likely to be diagnosed or treated than the wealthiest. Affordable semaglutide generics could reach exactly the populations where the treatment gap is widest.
Hopefully, as the availability and affordability of these drugs improve, India will see the same reductions in obesity, diabetes and cardiovascular events that the developed nations are already witnessing.This is especially critical since India has more people living with diabetes than any other country — 212 million as of 2022, roughly 1 in 4 of all cases worldwide.